What is complete response in AML?
The goal of treatment for acute myeloid leukemia (AML) is to put the leukemia into complete remission (the bone marrow and blood cell counts return to normal), preferably a complete molecular remission (no signs of leukemia in the bone marrow, even using sensitive lab tests), and to keep it that way.
How can you tell the difference between AML and CLL?
Summary. AML and CML are blood and bone marrow cancers that affect the same lines of white blood cells. AML comes on suddenly as very immature cells crowd out normal cells in the bone marrow. CML comes on more slowly, with the CML cells growing out of control.
What is MRD in leukemia?
y Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
What is MRD negative in AML?
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data …
Which leukemia is worse AML or ALL?
Is one more serious than the other? Both ALL and AML are very serious conditions that develop rapidly . According to a 2021 review, AML is the most common type of leukemia among adults, accounting for around 80% of all cases. Authors of the review observe that age plays an important role in survival rates for AML.
What are the four complications of CLL?
Infection. CLL patients may be more susceptible to infections due to either the CLL itself and/or its treatment.
How do you read MRD results?
An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment. y Doctors use MRD to measure the effectiveness of treatment and to predict which patients are at risk of relapse.